Cancers, Vol. 13, Pages 5222: FDG-PET/CT in Lymphoma: Where Do We Go Now?
Cancers, Vol. 13, Pages 5222: FDG-PET/CT in Lymphoma: Where Do We Go Now?
Cancers doi: 10.3390/cancers13205222
Authors:
Yassine Al Tabaa
Clement Bailly
Salim Kanoun
18F-fluorodeoxyglucose positron emission tomography combined with computed tomography (FDG-PET/CT) is an essential part of the management of patients with lymphoma at staging and response evaluation. Efforts to standardize PET acquisition and reporting, including the 5-point Deauville scale, have enabled PET to become a surrogate for treatment success or failure in common lymphoma subtypes. This review summarizes the key clinical-trial evidence that supports PET-directed personalized approaches in lymphoma but also points out the potential place of innovative PET/CT metrics or new radiopharmaceuticals in the future.
Source: Cancers - Category: Cancer & Oncology Authors: Yassine Al Tabaa Clement Bailly Salim Kanoun Tags: Perspective Source Type: research
More News: Cancer | Cancer & Oncology | Clinical Trials | CT Scan | Lymphoma | Mergers and Aquisitions | PET Scan